Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a distinct pathophysiologic entity from type 1 diabetes and represents a new model for autoimmune beta-cell failure, according to study results published in The Journal of Endocrinology & Metabolism.
Although immune checkpoint inhibitors can improve survival of patients with various advanced cancers, one of the rare immune-related adverse endocrine effects of this treatment is diabetes. Anti-programmed cell death 1 (PD-1) therapy has been associated with CIADM in ≤1% of patients. As there are limited studies to characterize CIADM, the researchers in the current study sought to describe its onset, natural history, treatment, glycemic variability, and predictive factors.
More here –> EndocrinologyAdvisor.com
